Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celularity, Inc. stock logo
CELU
Celularity
$1.33
+1.5%		$1.28
$0.56
▼
$2.55
$42.51M0.77142,437 shs30,597 shs
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$0.46
+1.0%		$1.32
$0.44
▼
$3.54
$49.33M2.314.96 million shs2.88 million shs
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
$1.78
-0.6%		$2.35
$1.71
▼
$16.00
$48.49M1.32299,946 shs169,351 shs
GTx, Inc. stock logo
GTXI
GTX
$0.53
$4.77
$0.74
▼
$25.60
$12.67M2.22390,540 shsN/A
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celularity, Inc. stock logo
CELU
Celularity
-7.75%-10.88%-6.43%+70.55%-42.29%
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-2.11%-25.48%-64.33%-72.28%-81.14%
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
+1.13%-3.24%-10.50%-44.06%-83.19%
GTx, Inc. stock logo
GTXI
GTX
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celularity, Inc. stock logo
CELU
Celularity
$1.33
+1.5%		$1.28
$0.56
▼
$2.55
$42.51M0.77142,437 shs30,597 shs
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$0.46
+1.0%		$1.32
$0.44
▼
$3.54
$49.33M2.314.96 million shs2.88 million shs
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
$1.78
-0.6%		$2.35
$1.71
▼
$16.00
$48.49M1.32299,946 shs169,351 shs
GTx, Inc. stock logo
GTXI
GTX
$0.53
$4.77
$0.74
▼
$25.60
$12.67M2.22390,540 shsN/A
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celularity, Inc. stock logo
CELU
Celularity
-7.75%-10.88%-6.43%+70.55%-42.29%
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-2.11%-25.48%-64.33%-72.28%-81.14%
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
+1.13%-3.24%-10.50%-44.06%-83.19%
GTx, Inc. stock logo
GTXI
GTX
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celularity, Inc. stock logo
CELU
Celularity
1.00
SellN/AN/A
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
2.38
Hold$5.501,083.56% Upside
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
2.50
Moderate Buy$15.00742.70% Upside
GTx, Inc. stock logo
GTXI
GTX
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest GTXI, CELU, ELTX, and CRBU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2026
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Neutral
10/7/2026
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeOutperform ➝ Sector Perform$1.00
10/7/2026
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform ➝ Market Perform$4.00 ➝ $1.00
10/7/2026
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeOutperform ➝ Market Perform$1.00
10/7/2026
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
Brookline Capital Markets logo
Brookline Capital Markets
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold
9/24/2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$8.00
8/27/2026
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
8/18/2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
8/14/2026
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$6.00 ➝ $5.00
8/5/2026
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
7/29/2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celularity, Inc. stock logo
CELU
Celularity
$26.55M1.63N/AN/A($1.32) per share-1.01
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$10.04M4.96N/AN/A$1.31 per share0.35
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
N/AN/AN/AN/A$0.09 per shareN/A
GTx, Inc. stock logo
GTXI
GTX
N/AN/AN/AN/A$1.09 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celularity, Inc. stock logo
CELU
Celularity
-$91.72M-$2.73N/AN/AN/A-374.87%N/A-64.45%11/13/2026 (Estimated)
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$148.12M-$1.08N/AN/AN/A-1,030.42%-89.11%-62.47%11/11/2026 (Estimated)
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
-$39.57M-$2.17N/AN/AN/AN/A-1,266.43%-139.94%11/12/2026 (Estimated)
GTx, Inc. stock logo
GTXI
GTX
-$38.42M-$1.65N/AN/AN/AN/A-104.19%-86.42%N/A

Latest GTXI, CELU, ELTX, and CRBU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
-$0.44N/AN/AN/AN/AN/A
11/11/2026Q3 2026
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$0.27N/AN/AN/A$1.60 millionN/A
9/29/2026Q1 2026
Celularity, Inc. stock logo
CELU
Celularity
N/A$0.02N/A$0.02N/A$3.85 million
8/13/2026Q2 2026
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$0.3240-$0.24+$0.0840-$0.24$2.28 million$1.50 million
8/13/2026Q2 2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
-$0.5375-$0.43+$0.1075-$0.43N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Celularity, Inc. stock logo
CELU
Celularity
N/AN/AN/AN/AN/A
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/AN/AN/AN/AN/A
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
N/AN/AN/AN/AN/A
GTx, Inc. stock logo
GTXI
GTX
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celularity, Inc. stock logo
CELU
Celularity
N/A
0.09
0.08
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/A
6.49
6.49
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
1.20
2.77
2.77
GTx, Inc. stock logo
GTXI
GTX
N/A
12.39
12.39

Institutional Ownership

CompanyInstitutional Ownership
Celularity, Inc. stock logo
CELU
Celularity
19.02%
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
77.51%
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
35.03%
GTx, Inc. stock logo
GTXI
GTX
9.50%

Insider Ownership

CompanyInsider Ownership
Celularity, Inc. stock logo
CELU
Celularity
17.30%
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
8.54%
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
50.90%
GTx, Inc. stock logo
GTXI
GTX
40.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celularity, Inc. stock logo
CELU
Celularity
11532.45 million26.84 millionOptionable
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
97107.21 million98.05 millionOptionable
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
N/A27.09 million13.30 millionNot Optionable
GTx, Inc. stock logo
GTXI
GTX
2124.05 millionN/ANot Optionable

Recent News About These Companies

NVIDIA celebrates 20 years of the GeForce 8800 GTX, its first CUDA-capable GPU
October 13 at 5:38 AM  |  tweaktown.comT
GeForce GTX 1080 Ti and Pascal GPU support comes to Windows XP thanks to new vibe coded drivers
October 5, 2026  |  tweaktown.comT
The 1972 Plymouth Road Runner GTX Chrysler tried to pretend it never built
October 4, 2026  |  msn.comhttps://www.msn.com/en-us/autos/general/the-1972-plymouth-road-runner-gtx-chrysler-tried-to-pretend-it-never-built/ar-AA2dsKIq
TITAN Xp finally runs on Windows XP, modder releases unofficial Pascal driver
October 3, 2026  |  videocardz.comV
NVIDIA releases new security driver for GTX 750 through GTX 10-series GPUs
October 1, 2026  |  tweaktown.comT
MeiraGTx: Promising Gene Therapy Platform but Early-Stage Risks Keep Risk/Reward Balanced at Hold
September 25, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/meiragtx-promising-gene-therapy-platform-but-early-stage-risks-keep-risk-reward-balanced-at-hold-ratings-news?utm_source=marketbeat.com&utm_medium=referral
MeiraGTx Appoints Veteran Investor Alan Sebulsky to Board
September 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/meiragtx-appoints-veteran-investor-alan-sebulsky-to-board?utm_source=marketbeat.com&utm_medium=referral
Rab Namche Hike GTX review: Premium waterproof trousers at a premium price
September 19, 2026  |  msn.comhttps://www.msn.com/en-us/shopping/general/rab-namche-hike-gtx-review-premium-waterproof-trousers-at-a-premium-price/ar-AA2cuX6U
1969 Plymouth GTX for sale with 27,600 miles shown
September 13, 2026  |  msn.comhttps://www.msn.com/en-us/autos/performance-cars/1969-plymouth-gtx-for-sale-with-27-600-miles-shown/ar-AA2c8jyt
The Jensen Interceptor GTX Isn't a Restomod. It's a Test of What a Heritage Name Is Worth
September 11, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/the-jensen-interceptor-gtx-isnt-a-restomod-its-a-test-of-what-a-heritage-name-is-worth/ar-AA2c34J3
Even a decade later, the GTX 1080 Ti isn't an easy card to replace
September 5, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/even-a-decade-later-the-gtx-1080-ti-isnt-an-easy-card-to-replace/ar-AA2bEpFM
Jensen's Interceptor GTX is a stylish V8 grand tourer
September 5, 2026  |  newsbytesapp.comN
Jensen Interceptor GTX is Britain’s 960-HP answer to the Ford Mustang GTD
September 5, 2026  |  msn.comhttps://www.msn.com/en-us/autos/performance-cars/jensen-interceptor-gtx-is-britain-s-960-hp-answer-to-the-ford-mustang-gtd/ar-AA2bDmx8
The Jensen Interceptor GTX in Photos
September 4, 2026  |  autos.yahoo.comhttps://autos.yahoo.com/new-vehicles-and-reviews/articles/jensen-interceptor-gtx-photos-120012097.html
Oof: 973hp Jensen Interceptor GTX revealed
September 4, 2026  |  pistonheads.comP
The Jensen Interceptor Returns as a 960-HP V-8 Track Monster, and Will Spawn Roadgoing Variants
September 4, 2026  |  msn.comhttps://www.msn.com/en-us/autos/news/the-jensen-interceptor-returns-as-a-960-hp-v-8-track-monster-and-will-spawn-roadgoing-variants/ar-AA2bxWIP
Wild new Jensen Interceptor GTX to spawn trio of super-GT V8s
September 4, 2026  |  msn.comhttps://www.msn.com/en-gb/news/other/wild-new-jensen-interceptor-gtx-to-spawn-trio-of-super-gt-v8s/ar-AA2by3RQ
New Jensen Interceptor GTX is a wild track-only 960bhp monster
September 4, 2026  |  msn.comhttps://www.msn.com/en-gb/news/other/new-jensen-interceptor-gtx-is-a-wild-track-only-960bhp-monster/ar-AA2bxxrO
All-New Jensen Interceptor GTX Is a 1,200-HP Track-Only Rocket With Blown 6.8-Liter Detroit Muscle
September 4, 2026  |  autoevolution.comA
The Jensen Interceptor GTX is a new V8 track-only monster (for now)…
September 4, 2026  |  msn.comhttps://www.msn.com/en-gb/news/other/the-jensen-interceptor-gtx-is-a-new-v8-track-only-monster-for-now/ar-AA2bxWMn

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celularity stock logo

Celularity NASDAQ:CELU

$1.33 +0.02 (+1.53%)
Closing price 04:00 PM Eastern
Extended Trading
$1.34 +0.00 (+0.38%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Caribou Biosciences stock logo

Caribou Biosciences NASDAQ:CRBU

$0.46 +0.00 (+1.00%)
Closing price 04:00 PM Eastern
Extended Trading
$0.46 0.00 (-1.01%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Elicio Therapeutics stock logo

Elicio Therapeutics NASDAQ:ELTX

$1.78 -0.01 (-0.56%)
Closing price 04:00 PM Eastern
Extended Trading
$1.85 +0.07 (+3.93%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

GTX stock logo

GTX NASDAQ:GTXI

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas